Nonviral siRNA Delivery to the Lung: Investigation of PEG−PEI Polyplexes and Their In Vivo Performance
Authors:
- Olivia M. MerkelOlivia M. Merkel
- Andrea BeyerleABAndrea Beyerle
- Damiano LibrizziDLDamiano Librizzi
- Andreas PfestroffAPAndreas Pfestroff
- Thomas M. BehrTBThomas M. Behr
- Brian SproatBSBrian Sproat
- Peter J. BarthPBPeter J. Barth
- Thomas KisselTKThomas Kissel
- 1 July 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 6 (4) , 1246-1260
Abstract
This study describes the physicobiological characterization of PEI− and PEG−PEI polyplexes containing partially 2′-OMe modified 25/27mer dicer substrate siRNAs (DsiRNAs) and their in vivo behavior regarding biodistribution and systemic bioavailability after pulmonary application as well as their ability to knock down gene expression in the lung. Biophysical characterization included circular dichroism of siRNA in polyplexes, condensation efficiency of polymers and in vitro stability. After in vivo application, biodistribution and kinetics of radiolabeled polyplexes were quantified and recorded over time in three-dimensional SPECT images and by end point scintillation counting. The influence on lung tissue and on the humoral and cellular immunosystem was investigated, and finally knockdown of endogenous gene expression in the lung was determined qualitatively. While all of the polymers used in our study were proven to effectively condense siRNA, stability of the complexes depended on the PEG grafting degree. Interestingly, PEI 25 kDa, which showed the least interaction with mucin or surfactant in vitro, performed poorly in vivo. Our nuclear imaging approach enabled us to follow biodistribution of the instilled nanocarriers over time and indicated that PEGylated nanocarriers are more suitable for lung application. While moderate proinflammatory effects were attributed to PEI25k−PEG(2k)10 nanocarriers, none of the treatments caused histological abnormalities. Our preliminary in vivo knockdown experiment suggests that PEG−PEI/siRNA complexes are promising nanomedicines for pulmonary siRNA delivery. These results encouraged us to further investigate possible adverse effects and to quantify in vivo gene silencing in the lung after intratracheal instillation of PEG−PEI/siRNA complexes.Keywords
This publication has 51 references indexed in Scilit:
- Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in miceJournal of Clinical Investigation, 2009
- RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune ResponseJournal of Virology, 2008
- Inhibition of influenza A virus replication by short double-stranded oligodeoxynucleotidesArchives of Virology, 2008
- Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAsBiochemical and Biophysical Research Communications, 2007
- In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic miceBlood, 2005
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacyNature Biotechnology, 2004
- Evidence that exogenous substances can be phagocytized by alveolar epithelial cells and transported into blood capillariesCell and tissue research, 2003
- Interaction of polycations with cell-surface negative charges of epithelial cellsBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992
- Effect of Lung Airway Branching Pattern and Gas Composition on Particle Deposition. II. Experimental Studies in Human and Canine LungsExperimental Lung Research, 1988
- Spermine and spermidine-induced B̄ to Ā transition of DNA in solutionJournal of Molecular Biology, 1979